You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma

  • Technology appraisal guidance
  • Reference number: TA226
  • Published:  22 June 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

TA226 Lymphoma (follicular non-Hodgkin's) - rituximab: review decision- August 2014: appendix a decision paper presented to the Institute's Guidance Executive

TA226 Lymphoma (follicular non-Hodgkin's) - rituximab: review decision- August 2014: appendix a decision paper presented to the Institute's Guidance Executive TA226 Lymphoma (follicular non-Hodgkin's) - rituximab: review decision- August 2014: appendix a decision paper presented to the Institute's Guidance Executive
26 August 2014
(106.59 Kb 31 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 26 August 2014

Back to top